Mark Tarnopolsky
Co-Applicant
Professor of Pediatrics and Medicine, Director of Neuromuscular and Neurometabolic Clinic, McMaster University Medical Center
CEO/CSO Exerkine Corporation
NMD4C Involvement: Pillar 1: Preclinical Science
Email MarkResearch Interests: Mitochondrial disease, Neurogenetic diagnostics, Neurometabolic disorders, MD therapeutics, Aging/sarcopenia, Obesity
Google Scholar profileBiography
Dr. Tarnopolsky is a neuromuscular and neurometabolic clinician-scientist who received an MD and PhD (Cell Biology and Metabolism) from McMaster University. He currently holds an endowed chair from McMaster Children’s Hospital Foundation in the area of neuromuscular and neurometabolic genetic disorders and follows over 1500 patients with myopathies, mitochondrial disorders and other neurogenetic disorders. He has published over 500 peer reviewed papers and has an h-index of 142. His research focuses on pharmacological, nutraceutical and exercise therapies for neuromuscular and neurometabolic disorders, aging, obesity and other disorders that affect the mitochondria and muscle function. He is the founder, CEO and CSO of Exerkine Corporation which is a bio-technology/nutraceutical company developing therapies for aging, obesity, muscular dystrophy and mitochondrial disorders.
Recent Publications
Foglia, SD, Adams, FC, Ramdeo, KR, Drapeau, CC, Turco, CV, Tarnopolsky, M et al.. Investigating the effects of dopamine on short- and long-latency afferent inhibition. J Physiol. 2024. PMID:38638084
Marshall, AE, Brady, L, Yeh, E, Mears, AJ, Lacaria, M, Chakraborty, P et al.. Next generation sequencing reveals novel compound heterozygous deletions in NDUFAF2 in a child with mitochondrial complex I deficiency, nuclear type 10. Am J Med Genet A. 2024. e63590 PMID:38477541
Schoser, B, Kishnani, PS, Bratkovic, D, Byrne, BJ, Claeys, KG, Díaz-Manera, J et al.. 104-week efficacy and safety of cipaglucosidase alfa plus miglustat in adults with late-onset Pompe disease: a phase III open-label extension study (ATB200-07). J Neurol. 2024.271 (5)2810-2823 PMID:38418563
Pan, LA, Naviaux, JC, Wang, L, Li, K, Monk, JM, Lingampelly, SS et al.. Metabolic features of treatment-refractory major depressive disorder with suicidal ideation. Transl Psychiatry. 2023.13 (1)393 PMID:38097555
Li, D, Wang, Q, Bayat, A, Battig, MR, Zhou, Y, Bosch, DG et al.. Spliceosome malfunction causes neurodevelopmental disorders with overlapping features. J Clin Invest. 2024.134 (1) PMID:37962958
Hartley, T, Marshall, D, Acker, M, Fooks, K, Gillespie, MK, Price, EM et al.. Evaluation of the diagnostic accuracy of exome sequencing and its impact on diagnostic thinking for patients with rare disease in a publicly funded health care system: A prospective cohort study. Genet Med. 2024.26 (2)101012 PMID:37924259
Leveille, CF, Zhu, XM, Chen, J, Burrow, SR, Wang, Y, Tarnopolsky, M et al.. Pediatric Peroneal Nerve Palsy Secondary to Fibular Osteochondroma. J Am Acad Orthop Surg Glob Res Rev. 2023.7 (10) PMID:37856702
D'Souza, AC, Wageh, M, Williams, JS, Colenso-Semple, LM, McCarthy, DG, McKay, AKA et al.. Menstrual cycle hormones and oral contraceptives: a multimethod systems physiology-based review of their impact on key aspects of female physiology. J Appl Physiol (1985). 2023.135 (6)1284-1299 PMID:37823207
Nigro, E, Grunebaum, E, Kamath, B, Licht, C, Malcolmson, C, Jeewa, A et al.. Case report: A case of spinal muscular atrophy in a preterm infant: risks and benefits of treatment. Front Neurol. 2023.14 1230889 PMID:37780708
Nederveen, JP, Mastrolonardo, AJ, Xhuti, D, Di Carlo, A, Manta, K, Fuda, MR et al.. Novel Multi-Ingredient Supplement Facilitates Weight Loss and Improves Body Composition in Overweight and Obese Individuals: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Nutrients. 2023.15 (17) PMID:37686725
See more on PubMed